Our 2014 approach to breakthrough invasive fungal infections

Georg Maschmeyer; Thomas F. Patterson

doi:10.1111/myc.12213

Our 2014 approach to breakthrough invasive fungal infections

Georg Maschmeyer, Thomas F. Patterson

Division of Infectious Diseases

Producción científica: Article › revisión exhaustiva

33 Citas (Scopus)

Resumen

Summary: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.

Idioma original	English (US)
Páginas (desde-hasta)	645-651
Número de páginas	7
Publicación	Mycoses
Volumen	57
N.º	11
DOI	https://doi.org/10.1111/myc.12213
Estado	Published - nov 1 2014

ASJC Scopus subject areas

Infectious Diseases
Dermatology

Acceder al documento

10.1111/myc.12213

Otros archivos y enlaces

Citar esto

@article{2376c711a61d48b29a37238c69698d88,

title = "Our 2014 approach to breakthrough invasive fungal infections",

abstract = "Summary: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.",

keywords = "Breakthrough fungal infection, Echinocandins, Fluconazole, Liposomal AmB, Posaconazole, Voriconazole",

author = "Georg Maschmeyer and Patterson, {Thomas F.}",

note = "Publisher Copyright: {\textcopyright} 2014 Blackwell Verlag GmbH.",

year = "2014",

month = nov,

day = "1",

doi = "10.1111/myc.12213",

language = "English (US)",

volume = "57",

pages = "645--651",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "11",

}

TY - JOUR

T1 - Our 2014 approach to breakthrough invasive fungal infections

AU - Maschmeyer, Georg

AU - Patterson, Thomas F.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Summary: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.

AB - Summary: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.

KW - Breakthrough fungal infection

KW - Echinocandins

KW - Fluconazole

KW - Liposomal AmB

KW - Posaconazole

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84907957745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907957745&partnerID=8YFLogxK

U2 - 10.1111/myc.12213

DO - 10.1111/myc.12213

M3 - Article

C2 - 24963554

AN - SCOPUS:84907957745

SN - 0933-7407

VL - 57

SP - 645

EP - 651

JO - Mycoses

JF - Mycoses

IS - 11

ER -

Our 2014 approach to breakthrough invasive fungal infections

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto